Asymmetrical Dimethylarginine (ADMA) Antibody

Background

Asymmetrical dimethylarginine (ADMA) is an endogenous molecule that competitively inhibits nitric oxide synthase (NOS), thereby reducing nitric oxide (NO) production and impairing vascular tone, endothelial function, and blood flow. As a key regulator of NO bioavailability, ADMA is a critical factor in cardiovascular health. Elevated ADMA levels are associated with endothelial dysfunction, hypertension, atherosclerosis, and heart failure, as insufficient NO contributes to inflammation, vascular rigidity, and oxidative stress. ADMA is metabolized by dimethylarginine dimethylaminohydrolase (DDAH), and any imbalance between ADMA production and clearance affects vascular and metabolic health. Beyond cardiovascular diseases, ADMA dysregulation is linked to chronic kidney disease, diabetes, and neurodegenerative disorders. ADMA serves as a biomarker for assessing cardiovascular and metabolic risks, and targeting the DDAH-ADMA-NO pathway is an emerging strategy to restore endothelial health and reduce vascular inflammation.